Nipruss (Sodium Nitroprusside Dihydrate)

Sodium nitroprusside, the active ingredient in Nipruss, is a vasodilator presented as a solution for injection for intravenous use. It is employed to rapidly lower blood pressure in hypertensive emergencies, to reduce cardiac workload in acute heart failure, and to provide controlled hypotension during surgical procedures.\n\nGNH India supplies Nipruss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nipruss, a potent vasodilator, is used in critical cardiovascular situations where rapid blood pressure control is required.\n\nHypertensive emergencies: produces an immediate and controlled reduction of severe arterial pressure.\nAcute heart failure: decreases preload and afterload, improving cardiac output and relieving pulmonary congestion.\nControlled hypotension during surgery: maintains a target low arterial pressure to reduce bleeding and improve surgical field visibility.

Nipruss may cause a range of adverse reactions that vary in frequency and severity.\n\nCommon Side Effects:\n- Headache: transient throbbing pain often related to rapid blood pressure changes.\n- Nausea or vomiting: gastrointestinal discomfort during infusion.\n- Flushing or warmth: sensation of heat due to vasodilation.\n- Reflex tachycardia: compensatory increase in heart rate.\n- Mild hypotension: excessive drop in blood pressure if infusion rate is too high.\n\nSerious or Rare Side Effects:\n- Cyanide toxicity: accumulation of cyanide metabolites leading to metabolic acidosis.\n- Methemoglobinemia: oxidation of hemoglobin impairing oxygen delivery.\n- Severe hypotension: profound blood pressure fall causing organ hypoperfusion.\n- Cardiac arrhythmias: irregular heart rhythms including ventricular ectopy.\n- Myocardial ischemia: reduced coronary perfusion despite vasodilation.\n- Anaphylactoid reactions: rare hypersensitivity with rash, bronchospasm, or shock.

When using Nipruss, clinicians should observe several safety measures to minimize risks.\n\nMonitor blood pressure continuously: adjust infusion to maintain target values.\nAdjust infusion rate based on response: titrate slowly to avoid abrupt hypotension.\nAvoid use in severe anemia or impaired renal function: reduced clearance may increase toxicity.\nCaution in pregnancy (Category C) and breastfeeding: weigh maternal benefit against fetal risk.\nEnsure availability of thiosulfate or other cyanide antidotes: prevent cyanide accumulation.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nipruss can interact with several agents that affect vascular tone or cyanide metabolism.\n\nMajor Interactions (Avoid):\n- Concurrent potent vasodilators (e.g., nitroglycerin): risk of severe hypotension.\n- MAO inhibitors: may potentiate vasodilatory effect.\n- Sodium nitrite: enhances cyanide formation.\n- Drugs that impair cyanide detoxification (e.g., chloramphenicol): increase toxicity risk.\n\nModerate Interactions (Monitor Closely):\n- Diuretics: may augment volume depletion and hypotension.\n- ACE inhibitors or ARBs: additive blood pressure lowering effect.\n- Beta‑blockers: may blunt reflex tachycardia, requiring careful monitoring.